Levetiracetam Stada (Levetiracetam)

Levetiracetam is an antiepileptic medication that modulates neuronal excitability and is employed to control seizure activity across several seizure types in patients with epilepsy.

• Partial seizures: reduces the frequency and severity of focal onset seizures in patients with epilepsy, improving quality of life.
• Generalized tonic‑clonic seizures: helps prevent convulsive episodes and associated loss of consciousness in generalized seizure disorders, reducing injury risk.
• Myoclonic seizures: decreases sudden, brief muscle jerks, improving control in myoclonic epilepsy, and supports daily functioning.

• Levetiracetam binds to the synaptic vesicle protein SV2A, a regulator of neurotransmitter release. This interaction modulates vesicle exocytosis, decreasing the release of excitatory neurotransmitters such as glutamate, and stabilizes neuronal membranes. The net effect is reduced neuronal hyper‑excitability, which underlies its anticonvulsant activity. It does not significantly affect GABAergic or sodium channel pathways, which contributes to its favorable drug‑interaction profile.

Levetiracetam may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Dizziness: transient sensation of light‑headedness.
• Fatigue: feeling unusually tired or weak.
• Headache: mild to moderate cranial pain.
• Irritability: mood changes or increased agitation.
• Nausea: upset stomach or feeling of queasiness.
• Somnolence: increased sleepiness or drowsiness.
• Coordination problems: unsteady gait or clumsiness.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Mood or behavior changes: depression, suicidal thoughts, or aggression.
• Blood disorders: thrombocytopenia or leukopenia.
• Stevens‑Johnson syndrome: rare severe skin reaction with blistering.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use.

• Renal function: adjust dose in patients with impaired renal clearance.
• Psychiatric history: monitor for mood changes, depression, or suicidal ideation.
• Pregnancy: use only if potential benefit justifies potential risk, as safety data are limited.
• Concomitant CNS depressants: observe for additive sedation or dizziness.
• Driving and machinery: advise patients to assess personal response before operating vehicles.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Levetiracetam has a low potential for pharmacokinetic interactions, but certain drug combinations require attention.

Major Interactions (Avoid)

• Carbamazepine: may reduce levetiracetam plasma levels, decreasing efficacy.
• Phenobarbital: can lower levetiracetam concentrations, risking seizure breakthrough.

Moderate Interactions (Monitor Closely)

• Alcohol: may enhance central nervous system depression, increasing dizziness or sedation.
• Other antiepileptics (e.g., valproate, phenytoin): monitor seizure control as additive effects may occur.
• Oral contraceptives: limited data suggest possible reduction in contraceptive effectiveness; advise additional contraceptive measures.